Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

3.277 -0.143 (-4.18%)
Streaming Delayed Price Updated: 11:45 AM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alterity Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the Biotech Showcase
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket ↗
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted. 
Via Benzinga
News headline image
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Prominently Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
ATH434 Phase 2 Data to be Presented at Opening Plenary Session 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.